Neovasc to Participate in H.C. Wainwright & Co. 22nd Annual Global Investment Conference

VANCOUVER and MINNEAPOLIS – (NewMediaWire) – September 08, 2020 – Neovasc, Inc. (“Neovasc” or the
“Company”) (NASDAQ, TSX: NVCN), a leader in
the development of minimally invasive transcatheter mitral valve replacement
technologies, and minimally invasive devices for the treatment of refractory
angina, today announced that its management team will be participating in the
22nd Annual H.C. Wainwright Global Investment Conference on September 14-16,
2020.  Fred Colen, Neovasc’s President and CEO, will present on September
15 at 3:30 pm EDT. 

A link to the live webcast of
Mr. Colen’s presentation will be available online through the investor
relations section of the Neovasc website at https://www.neovasc.com/investors/.
 Following the event, a replay of the
presentation will be archived on the Neovasc website for approximately 90 days.

About Neovasc Inc.

Neovasc is a specialty medical device company
that develops, manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include Reducer, for the treatment of
refractory angina, which is not currently commercially available in the United
States and has been commercially available in Europe since 2015, and Tiara, for
the transcatheter treatment of mitral valve disease, which is currently under
clinical investigation in the United States, Canada, Israel and Europe. For
more information, visit: www.neovasc.com.

Investors

Mike Cavanaugh

Westwicke/ICR

Phone: +1.646.877.9641

Mike.Cavanaugh@westwicke.com

Media

Sean Leous

Westwicke/ICR

Phone: +1.646.677.1839

Sean.Leous@icrinc.com

Forward-Looking Statement
Disclaimer

Certain statements in this news release
contain forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and applicable Canadian securities
laws that may not be based on historical fact.  When used herein, the
words “expect”, “anticipate”, “estimate”,
“may”, “will”, “should”, “intend,”
“believe”, and similar expressions, are intended to identify
forward-looking statements.  Forward-looking statements may involve, but
are not limited to, expectations as to the future growth of the Company, the
expansion of its product range and the growing cardiovascular marketplace.
Forward-looking statements are based on estimates and assumptions made by the
Company in light of its experience and its perception of historical trends,
current conditions and expected future developments, as well as other factors
that the Company believes are appropriate in the circumstances.  Many
factors could cause the Company’s actual results, performance or achievements
to differ materially from those expressed or implied by the forward-looking statements,
including those described in the “Risk Factors” section of the
Company’s Annual Report on Form 20-F and in the Management’s Discussion and
Analysis for the three and six months ended June 30, 2019 (copies of which may
be obtained at www.sedar.com or www.sec.gov).
 These factors should be considered carefully, and readers should not
place undue reliance on the Company’s forward-looking statements. The Company
has no intention and undertakes no obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.